CN115298169B - (1r,3s)-3-(5-氰基-4-苯基-1,3-噻唑-2-基氨基甲酰基)环戊烷羧酸的共晶 - Google Patents
(1r,3s)-3-(5-氰基-4-苯基-1,3-噻唑-2-基氨基甲酰基)环戊烷羧酸的共晶 Download PDFInfo
- Publication number
- CN115298169B CN115298169B CN202180021708.3A CN202180021708A CN115298169B CN 115298169 B CN115298169 B CN 115298169B CN 202180021708 A CN202180021708 A CN 202180021708A CN 115298169 B CN115298169 B CN 115298169B
- Authority
- CN
- China
- Prior art keywords
- crystal
- cyano
- ylcarbamoyl
- thiazol
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/02—Salts; Complexes; Addition compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382194.7A EP3882240A1 (en) | 2020-03-16 | 2020-03-16 | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
| EP20382194.7 | 2020-03-16 | ||
| PCT/EP2021/056506 WO2021185748A1 (en) | 2020-03-16 | 2021-03-15 | Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcabamoyl)cyclopentane carboxylic acid |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115298169A CN115298169A (zh) | 2022-11-04 |
| CN115298169B true CN115298169B (zh) | 2024-11-19 |
Family
ID=69953938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180021708.3A Active CN115298169B (zh) | 2020-03-16 | 2021-03-15 | (1r,3s)-3-(5-氰基-4-苯基-1,3-噻唑-2-基氨基甲酰基)环戊烷羧酸的共晶 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US12384754B2 (https=) |
| EP (2) | EP3882240A1 (https=) |
| JP (1) | JP7779846B2 (https=) |
| KR (1) | KR20220154791A (https=) |
| CN (1) | CN115298169B (https=) |
| AU (1) | AU2021237686B2 (https=) |
| BR (1) | BR112022018449A2 (https=) |
| CA (1) | CA3171894C (https=) |
| DK (1) | DK4121419T3 (https=) |
| ES (1) | ES3002084T3 (https=) |
| FI (1) | FI4121419T3 (https=) |
| HR (1) | HRP20241515T1 (https=) |
| HU (1) | HUE068886T2 (https=) |
| LT (1) | LT4121419T (https=) |
| MX (1) | MX2022011530A (https=) |
| PL (1) | PL4121419T3 (https=) |
| PT (1) | PT4121419T (https=) |
| RS (1) | RS66214B1 (https=) |
| SI (1) | SI4121419T1 (https=) |
| WO (1) | WO2021185748A1 (https=) |
| ZA (1) | ZA202211247B (https=) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101835766A (zh) * | 2007-10-02 | 2010-09-15 | 帕罗生物制药有限公司 | 作为腺苷a1受体拮抗体的新化合物 |
| CN102933205A (zh) * | 2010-04-28 | 2013-02-13 | 诺弗米克斯有限公司 | 西洛他唑共晶和组合物 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3592734T (lt) | 2017-03-06 | 2021-07-26 | Palobiofarma, S.L. | (1r,3s)-3-(5-ciano-4-fenil-1,3-tiazol-2-ilkarbamoil)ciklopentankarboksirūgšties amino druska |
-
2020
- 2020-03-16 EP EP20382194.7A patent/EP3882240A1/en not_active Withdrawn
-
2021
- 2021-03-15 CN CN202180021708.3A patent/CN115298169B/zh active Active
- 2021-03-15 EP EP21710531.1A patent/EP4121419B1/en active Active
- 2021-03-15 PT PT217105311T patent/PT4121419T/pt unknown
- 2021-03-15 MX MX2022011530A patent/MX2022011530A/es unknown
- 2021-03-15 HR HRP20241515TT patent/HRP20241515T1/hr unknown
- 2021-03-15 ES ES21710531T patent/ES3002084T3/es active Active
- 2021-03-15 AU AU2021237686A patent/AU2021237686B2/en active Active
- 2021-03-15 BR BR112022018449A patent/BR112022018449A2/pt unknown
- 2021-03-15 RS RS20241203A patent/RS66214B1/sr unknown
- 2021-03-15 CA CA3171894A patent/CA3171894C/en active Active
- 2021-03-15 HU HUE21710531A patent/HUE068886T2/hu unknown
- 2021-03-15 WO PCT/EP2021/056506 patent/WO2021185748A1/en not_active Ceased
- 2021-03-15 DK DK21710531.1T patent/DK4121419T3/da active
- 2021-03-15 US US17/906,367 patent/US12384754B2/en active Active
- 2021-03-15 KR KR1020227035871A patent/KR20220154791A/ko active Pending
- 2021-03-15 LT LTEPPCT/EP2021/056506T patent/LT4121419T/lt unknown
- 2021-03-15 SI SI202130224T patent/SI4121419T1/sl unknown
- 2021-03-15 PL PL21710531.1T patent/PL4121419T3/pl unknown
- 2021-03-15 FI FIEP21710531.1T patent/FI4121419T3/fi active
- 2021-03-15 JP JP2022555805A patent/JP7779846B2/ja active Active
-
2022
- 2022-10-13 ZA ZA2022/11247A patent/ZA202211247B/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101835766A (zh) * | 2007-10-02 | 2010-09-15 | 帕罗生物制药有限公司 | 作为腺苷a1受体拮抗体的新化合物 |
| CN102933205A (zh) * | 2010-04-28 | 2013-02-13 | 诺弗米克斯有限公司 | 西洛他唑共晶和组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| ES3002084T3 (en) | 2025-03-06 |
| JP7779846B2 (ja) | 2025-12-03 |
| KR20220154791A (ko) | 2022-11-22 |
| MX2022011530A (es) | 2022-10-13 |
| HUE068886T2 (hu) | 2025-02-28 |
| EP4121419A1 (en) | 2023-01-25 |
| CN115298169A (zh) | 2022-11-04 |
| FI4121419T3 (fi) | 2024-11-04 |
| US12384754B2 (en) | 2025-08-12 |
| LT4121419T (lt) | 2024-11-25 |
| CA3171894C (en) | 2025-03-11 |
| EP3882240A1 (en) | 2021-09-22 |
| WO2021185748A1 (en) | 2021-09-23 |
| US20230183195A1 (en) | 2023-06-15 |
| DK4121419T3 (da) | 2024-10-28 |
| ZA202211247B (en) | 2023-12-20 |
| AU2021237686A1 (en) | 2022-10-06 |
| BR112022018449A2 (pt) | 2022-11-01 |
| AU2021237686B2 (en) | 2026-04-09 |
| HRP20241515T1 (hr) | 2025-01-03 |
| PL4121419T3 (pl) | 2025-02-17 |
| CA3171894A1 (en) | 2021-09-23 |
| EP4121419B1 (en) | 2024-08-14 |
| PT4121419T (pt) | 2024-11-18 |
| SI4121419T1 (sl) | 2025-02-28 |
| RS66214B1 (sr) | 2024-12-31 |
| JP2023517722A (ja) | 2023-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10689380B1 (en) | Crystalline forms of valbenazine ditosylate | |
| JP2007302658A (ja) | イマチニブメシレートの多形フォーム及び新規結晶フォーム及び非晶フォーム並びにフォームαの調製方法 | |
| EP2918593B1 (en) | Benfotiamine polymorphs, preparation method and use thereof | |
| US12281182B2 (en) | Solid state forms of voclosporin | |
| US11427533B2 (en) | Crystalline polymorphs of bardoxolone methyl | |
| CN115298169B (zh) | (1r,3s)-3-(5-氰基-4-苯基-1,3-噻唑-2-基氨基甲酰基)环戊烷羧酸的共晶 | |
| US10583127B2 (en) | Amine salt of (1R, 3S)-3-(5-cyano-4-phenyl-1,3- thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid | |
| US11208382B2 (en) | Entinostat-containing compound, crystal form of compound thereof, and preparation method therefor and pharmaceutical composition thereof | |
| EA045045B1 (ru) | Сокристаллы (1r,3s)-3-(5-циано-4-фенил-1,3-тиазол-2-илкарбамоил)циклоопентанкарбоновой кислоты | |
| KR20050111629A (ko) | 무정형 심바스타틴 칼슘 및 그의 제조방법 | |
| WO2025228973A1 (en) | Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide | |
| US12391708B2 (en) | Crystalline Lorlatinib : fumaric acid and solid state form thereof | |
| US20240270733A1 (en) | Hydrate form of lazertinib mesylate, preparation method thereof and use thereof | |
| WO2024069574A1 (en) | Solid state forms of denifanstat | |
| WO2025257758A1 (en) | Solid state forms of navacaprant | |
| HK40020652A (en) | Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid | |
| HK40020652B (en) | Amine salt of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |